Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The purpose of this trial is to evaluate whether adding the drug rigosertib to the patient’s doctor’s choice (standard of care treatment) works better and is as safe as the doctor’s choice.

Patient Profile

Patients with Myelodysplastic Syndrome After Failure of drugs called Hypomethylating Agents (azacitidine (AZA) or decitabine (DEC)), 18 to 79 years of age, who have been treated with hypomethylating agents for </= 9 months.

Where’s this trial being run?

Cork University Hospital, Tallaght University Hospital, University Hospital Galway, and University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: Protocol 04-30
Number: 15-36
Full Title:

A Phase III International Randomised Controlled Study of Rigosertib versus Physicians Choice in MDS After Failing A Hypermethylating Agent.

Principal Investigator: Prof Helen Enright (Tallaght Hospital)
Type: Industry Sponsored


Recruitment Started: Global: October 2015
Ireland: May 2016
Global Recruitment Target: 225
Ireland Recruitment Target: 12